secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001477932-24-004835
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx Q2 revenue up 83% to $396K; H1 test sales exceed full-year 2023
--------------------------------------------------------------------------

- Q2 revenue $396K (+83% YoY); H1 revenue $567K (+55% YoY).
- Operating expenses down 24% YoY in Q2; targeting $10M annualized cost reductions.
- Cash $6.0M at June 30; closed $7M registered direct offering with up to $14.5M in milestone-linked warrants.
- Sold over 60,000 Nu.Q Vet Cancer Tests in H1 2024 (vs 58,000 full-year 2023); now available in 17 countries.
- Engaged PharmaVentures to advise on licensing deals for Nu.Q Cancer and Capture-PCR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793224004835/0001477932-24-004835-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793224004835/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-24-004835

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer